Leadership Team

As a research leader at both biotech and large pharmaceutical companies, Charlie has expertise across a broad range of therapeutic areas including neurology, neuromuscular, cardiovascular, ophthalmology and oncology. Preceding his tenure at Affinia Therapeutics, Charlie was chief scientific officer at Editas Medicine where his research group advanced the pioneering CRISPR gene-editing platform and medicines from program inception to IND application. Previously, he was vice president of genetically defined diseases and genomics at Bristol Myers Squibb, where he was responsible for developing the group’s strategy and building a pipeline of novel therapeutics with a focus on CNS and cardiovascular rare diseases. Before joining the industry, Charlie held academic positions at Vanderbilt University and the Whitehead Institute for Biomedical Research. Charlie earned a Ph.D. in biology and a B.S. in chemical engineering from Massachusetts Institute of Technology. He was a postdoctoral fellow at the Whitehead Institute.